Cargando…
Pralsetinib for the treatment of a RET-positive advanced non-small-cell lung cancer patient harboring both ANK-RET and CCDC6-RET fusions with coronary heart disease: a case report
BACKGROUND: Rearranged during transfection (RET) is one of the rare driver genes of non-small-cell lung cancer (NSCLC), having a gene fusion incidence of 1–2% in NSCLC. Before the emergence of specific RET inhibitors, multikinase inhibitors such as cabozantinib and vandetanib were tried for RET fusi...
Autores principales: | Meng, Yan, Li, Lulu, Wang, Huan, Chen, Xiaofang, Yue, Yali, Wang, Meiqing, Meng, Lingru, Li, Bafei, Li, Xiao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096366/ https://www.ncbi.nlm.nih.gov/pubmed/35571397 http://dx.doi.org/10.21037/atm-22-1237 |
Ejemplares similares
-
Durable response to low-dose pralsetinib in a renal insufficient patient with NSCLC harboring concurrent CCDC6-RET, LINCO1264-RET, and SEMA5A-RET fusions: A case report
por: Gu, Linping, et al.
Publicado: (2022) -
Response to Pralsetinib in Multi-Drug-Resistant Breast Cancer With CCDC6-RET Mutation
por: Zhao, Jing, et al.
Publicado: (2023) -
Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer
por: Gao, Ming, et al.
Publicado: (2023) -
Pralsetinib treatment for multiple RET fusions in lung
adenocarcinoma: a case report
por: Cao, Xiangming, et al.
Publicado: (2022) -
Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient
por: Wang, Sha-Sha, et al.
Publicado: (2022)